Sensitive Drug‐Resistance Assays Reveal Long‐Term Persistence of HIV‐1 Variants with the K103N Nevirapine (NVP) Resistance Mutation in Some Women and Infants after the Administration of Single‐Dose NVP: HIVNET 012 | Zendy

Tamara Flys | Zendy; Dwight V. Nissley | Zendy; Cassidy W. Claasen | Zendy; Dana Jones | Zendy; Chanjuan Shi | Zendy; Laura Guay | Zendy; Philippa Musoke | Zendy; Francis Mmiro | Zendy; Jeffrey N. Strathern | Zendy; J. Brooks Jackson | Zendy; James R. Eshleman | Zendy; Susan H. Eshleman | Zendy

Open Access

Sensitive Drug‐Resistance Assays Reveal Long‐Term Persistence of HIV‐1 Variants with the K103N Nevirapine (NVP) Resistance Mutation in Some Women and Infants after the Administration of Single‐Dose NVP: HIVNET 012

Author(s) -

Tamara Flys,

Dwight V. Nissley,

Cassidy W. Claasen,

Dana Jones,

Chanjuan Shi,

Laura Guay,

Philippa Musoke,

Francis Mmiro,

Jeffrey N. Strathern,

J. Brooks Jackson,

James R. Eshleman,

Susan H. Eshleman

Publication year - 2005

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/430742

Subject(s) - nevirapine , virology , medicine , drug resistance , lentivirus , resistance mutation , mutation , persistence (discontinuity) , human immunodeficiency virus (hiv) , microbiology and biotechnology , viral disease , antiretroviral therapy , biology , reverse transcriptase , viral load , polymerase chain reaction , gene , genetics , geotechnical engineering , engineering

The HIV Network for Prevention Trials (HIVNET) 012 trial showed that NVP resistance (NVPR) emerged in some women and children after the administration of single-dose nevirapine (SD-NVP). We tested whether K103N-containing human immunodeficiency virus (HIV)-1 variants persisted in women and infants 1 year or more after the administration of SD-NVP.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research